Kuros Biosciences AG (SWX:KURN)
Switzerland · Delayed Price · Currency is CHF 22.04
-0.44 (-1.96%)
Apr 24, 2026, 5:30 PM CET
Kuros Biosciences AG Revenue
In the year 2025, Kuros Biosciences AG had annual revenue of $146.06M USD with 71.51% growth. Kuros Biosciences AG had revenue of $82.58M in the half year ending December 31, 2025.
Revenue
$146.06M
Revenue Growth
+71.51%
P/S Ratio
7.60
Revenue / Employee
$820.55K
Employees
178
Market Cap
880.66M CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.06M | 60.90M | 71.51% |
| Dec 31, 2024 | 85.16M | 45.30M | 113.65% |
| Dec 31, 2023 | 39.86M | 20.41M | 104.92% |
| Dec 31, 2022 | 19.45M | 4.30M | 28.35% |
| Dec 31, 2021 | 15.15M | 10.59M | 231.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Novartis AG | 44.94B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 4.16B |
| Aevis Victoria | 1.04B |
| PolyPeptide Group AG | 362.47M |
| SKAN Group AG | 333.34M |
| Medartis Holding AG | 269.26M |
Kuros Biosciences AG News
- 10 days ago - Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 - GlobeNewsWire